TBC1D3B Inhibitors
TBC1D3B inhibitors belong to a class of chemical compounds designed to target and modulate the activity of TBC1D3B, a protein involved in cellular processes related to intracellular vesicle trafficking and membrane dynamics. TBC1D3B, short for TBC1 domain family member 3B, is a member of the TBC (Tre-2/Bub2/Cdc16) domain-containing protein family, which is characterized by its ability to regulate the function of small GTPases, particularly Rab GTPases. These GTPases play a pivotal role in controlling the trafficking and fusion of intracellular vesicles, thereby influencing various cellular processes such as endocytosis, exocytosis, and organelle transport.
TBC1D3B inhibitors are designed to selectively interfere with the function of TBC1D3B, either by blocking its enzymatic activity or altering its interaction with its target molecules, particularly Rab GTPases. By inhibiting TBC1D3B, these compounds may have the potential to modulate intracellular vesicle trafficking and membrane dynamics, which can have significant implications for cellular processes and functions. While the exact mechanisms and specific applications of TBC1D3B inhibitors may vary depending on the compound and its mode of action, their development and study can provide valuable insights into fundamental cellular processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
A selective inhibitor of ROCK (Rho-associated protein kinase), which may downregulate RhoA pathway signaling, potentially decreasing the activity of proteins regulated by this pathway, including those similar to TBC1D3B. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor that could disrupt the PI3K/AKT signaling cascade, which is often linked with growth factor signaling. This disruption could lead to a decrease in the activity of proteins that operate within this pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
Another MEK inhibitor that prevents the activation of MAPK/ERK, potentially altering the activity of proteins that function in connection with this pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that can modulate the mTOR signaling pathway, which is involved in cell growth and proliferation, potentially affecting proteins that are part of or interact with this pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A potent inhibitor of PI3K, like LY294002, wortmannin could affect signaling pathways involving PI3K, potentially modulating the activity of proteins within this pathway. | ||||||
Gö 6976 | 136194-77-9 | sc-221684 | 500 µg | $227.00 | 8 | |
A protein kinase C inhibitor that could alter signaling pathways involving PKC, potentially affecting the activity of proteins that interact with PKC-dependent signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
Inhibits p38 MAP kinase, which could affect proteins that are regulated by or interact with the p38 MAPK signaling pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, which could modulate proteins that are part of or influenced by the JNK signaling pathway. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
A Src family kinase inhibitor that could affect the activity of proteins involved in growth factor signaling pathways that interact with Src kinases. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
Another Src family kinase inhibitor, which could potentially alter the activity of proteins that are part of or are influenced by Src kinase signaling pathways. | ||||||